Investigator

Hardik Shah

Metabolomics platform Director · University of Chicago Medicine Comprehensive Cancer Center, Comprehensive Cancer Center

HSHardik Shah
Papers(1)
NNMT inhibition in ca…
Collaborators(10)
Hua LiangJanna HeideKaiting YangLisa SchweizerMaria Francesca AllegaMatthew D. HallMatthias MannQiaoshan LinRalph R. WeichselbaumSamarjit Patnaik
Institutions(5)
University Of ChicagoMax Planck Institute …National Center for A…Max Planck Institute …National Institutes O…

Papers

NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity

Cancer-associated fibroblasts (CAFs) have a pivotal cancer-supportive role, yet CAF-targeted therapies are lacking

62Works
1Papers
16Collaborators
Cell Line, TumorNeoplasmsIdiopathic Pulmonary FibrosisCancer-Associated FibroblastsOvarian NeoplasmsColonic NeoplasmsFerroptosis

Positions

2022–

Metabolomics platform Director

University of Chicago Medicine Comprehensive Cancer Center · Comprehensive Cancer Center

2018–

Researcher

Massachusetts General Hospital

2015–

Research Assistant

Memorial Sloan Kettering Cancer Center · Cell Metabolism Core Facility

2013–

Associate

Albert Einstein College of Medicine, Yeshiva University · Stable Isotope and Metabolomics Core Facility

2011–

Analytical Chemist

Procter and Gamble Co · Trace Analytical Core

2007–

Clinical Research Associate

Sun Pharma (India) · Bioequivalance

Education

2010

Master of Science

Fairleigh Dickinson University · Chemistry

2007

Bachelor of Pharmacy

Sant Gadge Baba Amravati University

Links & IDs
0000-0001-8408-5686